Fill in the form below and our experts will get back to you within 1 business day.
Accelerate your research with our versatile HEK293 expression platform. Ideal for rapid protein production, viral vector manufacturing, and structural biology studies. We offer both transient transfection and stable cell line development with optimized protocols for high yield and quality.
Trusted by leading research and pharmaceutical institutions
From gene to purified protein in as little as 2 weeks
Proper folding, glycosylation, and disulfide bonds
AAV, lentivirus, and adenovirus production
Our HEK293 expression services provide flexible solutions for rapid protein production, viral vector manufacturing, and research applications.
Rapid protein production using high-efficiency transient transfection. Perfect for quick turnaround projects, protein screening, and early research stages with expression typically achieved within 3-7 days.
Development of stable HEK293 cell pools or clones for consistent, long-term protein production. Suitable for structural biology, antibody characterization, and larger-scale production needs.
Proper protein folding, N-linked glycosylation, disulfide bonds, and phosphorylation for functional proteins.
Adaptable suspension cell lines for scalable production in shake flasks and bioreactors without attachment requirements.
Validated platform for AAV, lentivirus, and adenovirus vector production for gene therapy applications.
Get a customized quote for your HEK293 expression project.
Our optimized HEK293 expression system delivers superior results for diverse applications.
Proprietary transfection reagents and protocols achieving >90% transfection efficiency with minimal toxicity for optimal protein yield.
Multiple HEK293 derivatives including HEK293T, HEK293F, HEK293E, and GnTI-deficient lines for specific expression requirements.
Suspension-adapted cells enabling seamless scale-up from milliliter shake flasks to 100L bioreactors with consistent performance.
Comprehensive specifications to meet your research and production requirements.
| Parameter | Transient Expression | Stable Pool | Stable Clone |
|---|---|---|---|
| Expression Timeline | 2-3 weeks | 4-6 weeks | 8-12 weeks |
| Scale Range | 1mL - 100L | 1L - 100L | 1L - 100L |
| Typical Yield | 1-50 mg/L | 100-500 mg/L | Up to 1 g/L |
| Consistency | Batch-to-batch variation | High consistency | Very high consistency |
| Best For | Screening, rapid needs | Medium-scale production | Large-scale, long-term |
| Purification | Affinity + buffer exchange | Multi-step available | Full characterization |
Our proven workflow ensures quality and efficiency at every stage.
Plasmid preparation and QC
HEK293 cell expansion
High-efficiency transfection
Protein expression and harvest
Purification and QC release
Our HEK293 expression services support research and development in multiple fields.
HEK293 cells produce mammalian proteins with proper folding and post-translational modifications essential for structural studies by cryo-EM, X-ray crystallography, and NMR.
Rapid production of monoclonal antibodies, Fc-fusion proteins, and antibody fragments for research, preclinical studies, and screening applications.
Validated platform for viral vector production including AAV, lentivirus, and adenovirus for gene therapy and cell therapy applications.
Trusted by researchers worldwide for quality and reliability.
"The transient expression service was exactly what we needed for our structural biology project. We received high-quality protein in just 2 weeks. The team was very responsive and accommodating with our timeline."
"We used the stable cell line development service for our antibody characterization program. The cell pool they developed showed excellent productivity and stability. Highly recommend for antibody discovery projects."
"Professional service with excellent communication. The AAV production was high quality and worked perfectly in our gene therapy experiments. A reliable partner for our viral vector needs."
Our platform is backed by peer-reviewed research.
Schütz A, et al. STAR Protoc. 2023.
Comprehensive decision guide comparing expression systems including HEK293, with emphasis on transient transfection advantages and high transfection efficiency.
Zhou J, et al. Antibodies. 2023.
Systematic comparison of Expi293F and ExpiCHO-S cells for transient antibody production, highlighting Expi293F excellence for kappa and lambda light chain antibodies.
Sun H, et al. PLOS ONE. 2023.
Development of robust methods for HEK293-derived stable pools producing proteins with fewer cleavage fragments and higher yields than transient transfection.
Heng ZSL, et al. Antib Ther. 2022.
Systematic optimization of HEK293E transfection and culture parameters achieving 452% increase in kappa chain and 252% increase in full antibody production.
Green EA, et al. BMC Biotechnology. 2023.
Comprehensive comparison of HEK293 transient versus stable platforms, showing stable batch culture produces 2.1x more protein with stable clone yields up to 140 mg/L.
Find answers to common questions about our service.
Get a customized quote for your Custom HEK Cell Protein Expression Service project. Our experts will respond within 24 hours.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.